Vera Therapeutics posted a net loss of $109.5 million, or $1.52 per share, in Q2 2026, widening from a loss of $76.5 million.
Net cash used in operating activities totaled $206.8 million for the six months ended June 30, 2026.
Cash, cash equivalents and marketable securities were $499.2 million as of June 30, 2026; up to $425 million remained available under its debt facility.
TRUTAKNA won FDA accelerated approval in adult primary IgA nephropathy patients at risk of progression; U.S. launch is underway.
ORIGIN 3 final efficacy analysis is expected in Q3 2026; an sBLA submission is targeted for Q4 2026, with potential full approval expected in 2027.
VERA•
